These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35680596)

  • 21. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
    Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
    J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
    Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ
    J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia.
    Gayet M; Leymarie V; Derouault P; Guérin E; Vaidié J; Pascal V; Boulin M; Dmytruk N; Chauzeix J; Trimoreau F; Gachard N; Feuillard J; Rizzo D
    Cytometry B Clin Cytom; 2022 Jan; 102(1):62-69. PubMed ID: 33634586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
    Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
    Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Successful detection of MYD88 L265P mutation in Waldenström's macroglobulinemia complicated with myelofibrosis using highly sensitive digital PCR].
    Nawata R; Sugiyama A; Harada K; Shinohara K; Yujiri T
    Rinsho Ketsueki; 2019; 60(8):903-909. PubMed ID: 31484887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
    Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
    Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
    Mori N; Ohwashi M; Yoshinaga K; Mitsuhashi K; Tanaka N; Teramura M; Okada M; Shiseki M; Tanaka J; Motoji T
    PLoS One; 2013; 8(11):e80088. PubMed ID: 24224040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
    Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P
    Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acid.
    Albitar A; Ma W; DeDios I; Estella J; Agersborg S; Albitar M
    Int J Lab Hematol; 2016 Apr; 38(2):133-40. PubMed ID: 26797804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.
    Hunter ZR; Xu L; Yang G; Tsakmaklis N; Vos JM; Liu X; Chen J; Manning RJ; Chen JG; Brodsky P; Patterson CJ; Gustine J; Dubeau T; Castillo JJ; Anderson KC; Munshi NM; Treon SP
    Blood; 2016 Aug; 128(6):827-38. PubMed ID: 27301862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice.
    Østergaard S; Schejbel L; Breinholt MF; Pedersen MØ; Hammer T; Munksgaard L; Nørgaard P; Høgdall E; Gjerdrum LMR; Nielsen TH
    Leuk Lymphoma; 2024 Jun; 65(6):758-767. PubMed ID: 38340359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia.
    Moreno DF; Fernández de Larrea C
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):659-670. PubMed ID: 37211494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.
    Ondrejka SL; Lin JJ; Warden DW; Durkin L; Cook JR; Hsi ED
    Am J Clin Pathol; 2013 Sep; 140(3):387-94. PubMed ID: 23955458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
    Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].
    Tao Y; Wang S; Wang L; Wu M; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):993-997. PubMed ID: 35045669
    [No Abstract]   [Full Text] [Related]  

  • 36. MYD88 L265P mutation in Waldenstrom macroglobulinemia.
    Poulain S; Roumier C; Decambron A; Renneville A; Herbaux C; Bertrand E; Tricot S; Daudignon A; Galiègue-Zouitina S; Soenen V; Theisen O; Grardel N; Nibourel O; Roche-Lestienne C; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
    Blood; 2013 May; 121(22):4504-11. PubMed ID: 23532735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia.
    Kim JA; Im K; Park SN; Kwon J; Choi Q; Hwang SM; Sekiguchi N; Yoon SS; Lee DS; Kim SY
    Biomed Res Int; 2014; 2014():363540. PubMed ID: 24895570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
    Treon SP; Gustine J; Xu L; Manning RJ; Tsakmaklis N; Demos M; Meid K; Guerrera ML; Munshi M; Chan G; Chen J; Kofides A; Patterson CJ; Yang G; Liu X; Severns P; Dubeau T; Hunter ZR; Castillo JJ
    Br J Haematol; 2018 Feb; 180(3):374-380. PubMed ID: 29181840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
    Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
    Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Nodal lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia: a clinicopathological and prognostical study].
    Zhang DD; Hu PZ; Li P; Jiang GZ; Yin YH; Wang GN; Zhao WG; Zhang YP; Li WC
    Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):592-597. PubMed ID: 34078045
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.